Pharmacodynamic effects of orally administered dexlipotam on endothelial function in type 2-diabetic patients

2007 ◽  
Vol 45 (07) ◽  
pp. 385-393 ◽  
Author(s):  
S. Vossler ◽  
S. Füllert ◽  
F. Schneider ◽  
E. Haak ◽  
T. Haak ◽  
...  
Keyword(s):  
Endothelial Function ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Pharmacodynamic Effects ◽  
Type 2 Diabetic

Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients

2010 ◽  
Vol 118 (10) ◽  
pp. 607-615 ◽  
Author(s):  
Sandra J. Hamilton ◽  
Gerard T. Chew ◽  
Timothy M.E. Davis ◽  
Gerald F. Watts
Keyword(s):  
Endothelial Dysfunction ◽  
Endothelial Function ◽  
Statin Therapy ◽  
Brachial Artery ◽  
Ldl Cholesterol ◽  
Density Lipoprotein ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Dyslipidaemia contributes to endothelial dysfunction and CVD (cardiovascular disease) in Type 2 diabetes mellitus. While statin therapy reduces CVD in these patients, residual risk remains high. Fenofibrate corrects atherogenic dyslipidaemia, but it is unclear whether adding fenofibrate to statin therapy lowers CVD risk. We investigated whether fenofibrate improves endothelial dysfunction in statin-treated Type 2 diabetic patients. In a cross-over study, 15 statin-treated Type 2 diabetic patients, with LDL (low-density lipoprotein)-cholesterol <2.6 mmol/l and endothelial dysfunction [brachial artery FMD (flow-mediated dilatation) <6.0%] were randomized, double-blind, to fenofibrate 145 mg/day or matching placebo for 12 weeks, with 4 weeks washout between treatment periods. Brachial artery FMD and endothelium-independent NMD (nitrate-mediated dilatation) were measured by ultrasonography at the start and end of each treatment period. PIFBF (post-ischaemic forearm blood flow), a measure of microcirculatory endothelial function, and serum lipids, lipoproteins and apo (apolipoprotein) concentrations were also measured. Compared with placebo, fenofibrate increased FMD (mean absolute 2.1±0.6 compared with −0.3±0.6%, P=0.04), but did not alter NMD (P=0.75). Fenofibrate also increased maximal PIFBF {median 3.5 [IQR (interquartile range) 5.8] compared with 0.3 (2.1) ml/100 ml/min, P=0.001} and flow debt repayment [median 1.0 (IQR 3.5) compared with −1.5 (3.0) ml/100 ml, P=0.01]. Fenofibrate lowered serum cholesterol, triacylgycerols (triglycerides), LDL-cholesterol, apoB-100 and apoC-III (P≤0.03), but did not alter HDL (high-density lipoprotein)-cholesterol or apoA-I. Improvement in FMD was inversely associated with on-treatment LDL-cholesterol (r=−0.61, P=0.02) and apoB-100 (r=−0.54, P=0.04) concentrations. Fenofibrate improves endothelial dysfunction in statin-treated Type 2 diabetic patients. This may relate partly to enhanced reduction in LDL-cholesterol and apoB-100 concentrations.

Endothelial function and biochemical vascular markers in first-degree relatives of type 2 diabetic patients: the effect of exercise training

Metabolism ◽  
2006 ◽  
Vol 55 (11) ◽  
pp. 1508-1515 ◽  
Author(s):  
Torben Østergård ◽  
Birgit Nyholm ◽  
Troels K. Hansen ◽  
Lars M. Rasmussen ◽  
Jørgen Ingerslev ◽  
...  
Keyword(s):  
Exercise Training ◽  
Endothelial Function ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
First Degree Relatives ◽  
Vascular Markers ◽  
Type 2 Diabetic

Impact of cardiac magnetic resonance on endothelial function in type 2 diabetic patients

2015 ◽  
Vol 239 (1) ◽  
pp. 131-136
Author(s):  
Guangda Xiang ◽  
Lin Xiang ◽  
Honglin He ◽  
Junxia Zhang ◽  
Jing Dong
Keyword(s):  
Cardiac Magnetic Resonance ◽  
Magnetic Resonance ◽  
Endothelial Function ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Evaluation of the Vasoprotective Effects of Metformin versus Glibenclamide in Type 2 Diabetic Patients

2021 ◽  
pp. 6409-6412
Author(s):  
Zainab H. Fathi ◽  
Jehan A. Mohammad ◽  
Marwah H. Mohammed
Keyword(s):  
Endothelial Function ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Metformin Monotherapy ◽  
Group A ◽  
Glucose Lowering Effect ◽  
Group B ◽  
Oral Hypoglycemic Drugs ◽  
Type 2 Diabetic

Adiponectin (APN) is an adipokine with anti-inflammatory and anti-atherogenic properties decreased in type 2 diabetes mellitus (T2DM) that may influence endothelial function by regulating serum nitric oxide (NO) levels. The current study aimed to investigate the effect of two oral hypoglycemic drugs, Metformin and Glibenclamide (GLC), on circulating APN and NO levels and to find a correlation between APN and NO levels in type 2 diabetic patients. Fifty males and females previously diagnosed with T2DM were conducted in this trial and classified into groups: Group A involved 18 untreated patients with T2DM, group B involved 16 patients receiving Metformin monotherapy (1000 mg/day) for up to 1 year and group C involved 16 patients receiving GLC (5 mg/day) for up to 1 year. Circulating APN and NO were measured. Compared to GLC, Metformin therapy showed a significant increase in APN and NO levels in type 2 diabetic patients. Our findings established that Metformin has a protective effect on endothelial function, including increased APN and NO bioavailability, beyond its glucose-lowering effect.

Sign in / Sign up

Export Citation Format

Share Document